Achillion Pharmaceuticals, Inc., a pharmaceutical company dedicated to bringing new treatments to patients with infectious disease, announced that it will present a corporate update at the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at the Waldorf-Astoria Hotel in New York. Michael Kishbauch, President and Chief Executive Officer of Achillion, will make the presentation. Achillion is focused on solutions for the most challenging problems in infectious disease including the hepatitis C virus (HCV) and resistant bacterial infections. According to an Achillion news release, a live audio and video broadcast will be available on the Company’s website,http://www.achillion.com, under the “News Center” section, to be archived on the site for 30 days. Those who wish to view the live broadcast should connect to Achillion’s website several minutes prior to the start of the presentation.
CardioFocus, Inc., a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), is the developer of the HeartLight® Endoscopic Ablation System for the treatment of AF. The HeartLight technology possesses unique capabilities for the treatment of AF, enabling physicians to directly see the tissue to be ablated, and offering a laser energy source to facilitate the creation of durable lesions.
As of late 2012, more than 1,000 clinical cases have been performed worldwide using the HeartLight technology. CardioFocus recently held an expert symposium in Boston, MA, to review the clinical application of HeartLight and observations from the first 1,000 cases.
Presentations covered techniques for utilizing the endoscopically-guided ablation system, the desired location of pulmonary vein isolation, and the impact of HeartLight laser energy titration on achieving durable results. Discussion covered clinical results obtained using HeartLight in comparison to systems using alternative energy sources.
Temple University Hospital is testing the RePneu® Lung Volume Reduction Coils as part of a study on lung volume reduction coil treatment in patients with emphysema, which is being conducted by California‐based PneumRx, the company that makes the coils. The testing seeks to determine whether implanting miniature coils in the airways of diseased lungs of emphysema patients can improve breathing, activity levels and quality of life.
The coils – which are made with Nitinol, a metal commonly used in medical implants – compress damaged tissue, enabling healthier portions of the lung to function more efficiently, easing breathing in the process. The coils stand as a minimally invasive alternative to lung volume reduction surgery. European studies have shown that patients treated with the coils experience improved quality of life, greater ability to exercise and reduced breathlessness.
RePneu coils are delivered through a bronchoscope in a short, non‐surgical procedure performed under conscious sedation or general anesthesia. A typical procedure takes approximately 30 minutes and involves the implantation of approximately 10 coils.